| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $434,600 | 4 | 100 |
Sells | $0 | 0 | 0 |
| Higuchi John W. | director | 2 | $333,350 | 0 | $0 | $333,350 |
| Patel Mahesh V. | Chief Executive Officer | 2 | $101,250 | 0 | $0 | $101,250 |
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Over the last 12 months, insiders at Lipocine Inc. have bought $434,600 and sold $0 worth of Lipocine Inc. stock.
On average, over the past 5 years, insiders at Lipocine Inc. have bought $233,738 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Higuchi John W. (director) — $333,350. Patel Mahesh V. (Chief Executive Officer) — $101,250.
The last purchase of 40,000 shares for transaction amount of $81,200 was made by Higuchi John W. (director) on 2026‑04‑07.
| 2026-04-07 | Higuchi John W. | director | 40,000 0.7456% | $2.03 | $81,200 | +13.00% | ||
| 2026-04-06 | Higuchi John W. | director | 123,000 2.3869% | $2.05 | $252,150 | +16.49% | ||
| 2026-04-06 | Patel Mahesh V. | Chief Executive Officer | 25,000 0.4804% | $2.03 | $50,750 | +16.49% | ||
| 2026-04-02 | Patel Mahesh V. | Chief Executive Officer | 25,000 0.1003% | $2.02 | $50,500 | +10.24% | ||
| 2023-05-25 | Patel Mahesh V. | CEO and President | 8,706 0.1614% | $5.03 | $43,791 | -23.22% | ||
| 2023-03-24 | Patel Mahesh V. | CEO and President | 150,000 0.0107% | $0.32 | $48,000 | -21.29% | ||
| 2023-03-20 | Ono Richard Dana | director | 4,000 0.0003% | $0.34 | $1,360 | -28.03% | ||
| 2023-03-17 | Patel Mahesh V. | CEO and President | 50,000 0.0032% | $0.33 | $16,500 | -32.85% | ||
| 2022-11-22 | Papapetropoulos Spyros | director | 21,739 0.0015% | $0.47 | $10,217 | -37.21% | ||
| 2022-11-14 | Patel Mahesh V. | CEO and President | 75,000 0.0051% | $0.39 | $29,250 | -23.07% | ||
| 2022-09-27 | Patel Mahesh V. | CEO and President | 100,000 0.0069% | $0.41 | $41,000 | -19.07% | ||
| 2022-05-17 | Fogarty Krista | Principal Accounting Officer | 12,500 0.0008% | $0.86 | $10,750 | -48.85% | ||
| 2022-05-16 | Patel Mahesh V. | CEO and President | 50,000 0.0032% | $0.77 | $38,495 | -39.61% | ||
| 2021-11-18 | Patel Mahesh V. | CEO and President | 25,000 0.0017% | $1.09 | $27,250 | -21.10% | ||
| 2020-12-31 | Sale | Higuchi John W. | director | 6,700 0.0005% | $1.35 | $9,054 | -0.74% | |
| 2020-12-16 | Sale | Patel Mahesh V. | Chief Executive Officer | 15,000 0.0013% | $1.35 | $20,250 | -1.45% | |
| 2020-12-16 | Sale | BROWN MORGAN R | EVP and CFO | 8,437 0.0007% | $1.35 | $11,390 | -1.45% | |
| 2020-12-04 | Sale | Patel Mahesh V. | Chief Executive Officer | 43,500 0.004% | $1.57 | $68,134 | -11.04% | |
| 2020-12-04 | Sale | BROWN MORGAN R | Chief Financial Officer | 17,250 0.0016% | $1.57 | $27,024 | -11.04% | |
| 2020-03-17 | Higuchi John W. | director | 220,000 0.0309% | $0.32 | $69,542 | +337.50% |
| Higuchi John W. | director | 203797 2.472% | $499,302.65 | 4 | 1 | +337.5% |
| Patel Mahesh V. | Chief Executive Officer | 160679 1.949% | $393,663.55 | 18 | 4 | +40.01% |
| BROWN MORGAN R | EVP and CFO | 194504 2.3593% | $476,534.80 | 0 | 4 | |
| Papapetropoulos Spyros | director | 21739 0.2637% | $53,260.55 | 1 | 0 | <0.0001% |
| Ono Richard Dana | director | 14125 0.1713% | $34,606.25 | 2 | 1 | +6.64% |
| Fogarty Krista | Principal Accounting Officer | 12500 0.1516% | $30,625.00 | 1 | 0 | <0.0001% |
| Bass Gregory Brooks | Chief Commercial Officer | 5625 0.0682% | $13,781.25 | 0 | 1 | |
| HILL STEPHEN A | director | 5250 0.0637% | $12,862.50 | 1 | 1 | +48.99% |
| Fink Jeffrey Arvin | director | 937 0.0114% | $2,295.65 | 0 | 1 |
$1,993,425 | 46 | -21.90% | $16.08M | |
$30,257,839 | 29 | -15.72% | $23.91M | |
Lipocine Inc. (LPCN) | $555,628 | 21 | 43.52% | $20.2M |
$114,619,342 | 20 | -7.41% | $19.67M | |
$742,412 | 14 | -50.36% | $19.38M | |
$1,246,170 | 12 | 65.67% | $20.72M | |
$365,792 | 12 | -15.77% | $18.94M | |
$4,146,041 | 11 | -40.86% | $16.68M | |
$176,752 | 10 | -28.86% | $23.38M | |
$4,176,565 | 9 | 18.77% | $22.6M | |
$8,971,546 | 8 | 6.18% | $19.9M | |
$654,995 | 7 | -60.00% | $20.68M | |
$114,586 | 6 | -12.52% | $25.14M | |
$5,117,729 | 6 | -52.29% | $16.46M | |
$2,060,158 | 5 | -21.35% | $15.58M | |
$1,124,966 | 4 | 0.87% | $18.96M | |
$35,811 | 1 | -10.94% | $23.7M | |
$5,512,500 | 1 | -7.91% | $28.25M | |
$150,000 | 1 | 5.48% | $24.31M |
| Increased Positions | 15 | +71.43% | 1M | +217.17% |
| Decreased Positions | 6 | -28.57% | 48,834 | -9.23% |
| New Positions | 8 | New | 1M | New |
| Sold Out Positions | 4 | Sold Out | 24,832 | Sold Out |
| Total Postitions | 30 | +42.86% | 2M | +207.95% |
| Vanguard Group Inc | $1,775.00 | 3.7% | 221,867 | -3,009 | -1.34% | 2025-09-30 |
| Blackrock, Inc. | $714.00 | 1.49% | 89,272 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $489.00 | 1.02% | 61,076 | 0 | 0% | 2025-09-30 |
| Susquehanna International Group, Llp | $374.00 | 0.78% | 46,761 | +742 | +1.61% | 2025-09-30 |
| Renaissance Technologies Llc | $289.00 | 0.6% | 36,097 | +1,300 | +3.74% | 2025-09-30 |
| State Street Corp | $149.00 | 0.31% | 18,626 | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $114.00 | 0.24% | 14,247 | +14,247 | New | 2025-09-30 |
| Northern Trust Corp | $105.00 | 0.22% | 13,160 | 0 | 0% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $97.00 | 0.2% | 12,140 | -11,722 | -49.12% | 2025-09-30 |
| Barclays Plc | $75.00 | 0.16% | 9,412 | 0 | 0% | 2025-09-30 |